시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 위마비 시장 보고서(2025년)
Gastroparesis Global Market Report 2025
상품코드 : 1824382
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

위마비 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 5.3%로 87억 8,000만 달러로 성장할 것으로 예상됩니다. 예측 기간의 성장은 새로운 치료 옵션 개발, 개인화된 의료 접근법 확대, 디지털 건강 솔루션 통합, 건강 관리 인프라 증가, 조기 진단에 대한 관심 증가로 인한 것입니다. 예측기간의 주요 동향으로는 위전자극요법의 진보, 줄기세포요법의 연구확대, 저침습 외과적 개입의 채택, 웨어러블 건강 모니터링 기기의 사용 증가, 환자 중심의 케어 모델의 중시 등이 있습니다.

향후 5년간의 성장률 5.3%라고 하는 예측은 전회의 예측으로부터 0.2%의 소폭 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 캐나다와 독일의 위 전기 자극제와 프로키네틱 약물의 무역 장벽은 치료비를 40% 증가시킬 수 있으며, 환자는 더 효과적인 선택을 선택할 수 없게 되어 난치성 사례의 입원이 증가합니다. 또한 상호 관세와 무역 긴장 증가와 제한으로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 더 광범위하게 가해질 수 있습니다.

예상되는 헬스케어 지출 증가는 향후 수년간 위마비 시장의 확대를 견인할 것으로 보입니다. 건강 관리 지출은 병원, 의료 전문가, 간호, 치과 치료, 의약품, 공중 보건 이니셔티브와 관련된 비용을 포함하여 건강 관리 서비스에 할당되는 총 자원을 포함합니다. 고령화, 의료기술의 진보, 만성질환 증가, 충실한 헬스케어 서비스에 대한 소비자의 기대 증가 등의 요인이 헬스케어 지출 증가에 기여하고 있습니다. 이러한 증가는 연구 개발에 대한 추가 재정 지원, 치료 옵션의 확대, 전문적인 의료 서비스에 대한 환자 접근 개선 등 위마비 시장에 이익을 가져옵니다. 예를 들어 영국 정부 기관인 Office for National Statistics의 보고서에 따르면 영국의 건강 관리 지출은 2022-2023년에 걸쳐 5.6% 증가했습니다. 2023년에 영국의 건강 관리 지출은 약 3,176억 3,000만 달러(2,920억 파운드)에 이릅니다. 이와 같이 헬스케어 지출의 성장이 위마비 시장을 추진하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

SHW
영문 목차

영문목차

Gastroparesis is a medical condition characterized by the impairment or weakening of the stomach muscles, leading to the delayed emptying of stomach contents into the small intestine. The treatment of gastroparesis involves medications aimed at stimulating stomach emptying, managing underlying conditions, and surgical interventions.

The primary treatment modalities for gastroparesis include medications, dietary modifications, medical devices, and other approaches. Medications are substances that interact with the body's biological processes to produce a desired effect. Prokinetic drugs, antiemetics, botulinum toxin injections, antidepressants, and other medications are utilized to diagnose, treat, cure, or prevent gastroparesis. These medications are employed in the treatment of various types of gastroparesis, including idiopathic, diabetic, post-surgical, and others, in both pediatric and adult patients. They are distributed through retail pharmacies, hospital pharmacies, and other channels, making them accessible to hospitals and clinics, ambulatory surgical centers, and home care settings.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The gastroparesis research report is one of a series of new reports from The Business Research Company that provides gastroparesis market statistics, including the gastroparesis industry's global market size, regional shares, competitors with gastroparesis market share, detailed gastroparesis market segments, market trends and opportunities, and any further data you may need to thrive in the gastroparesis industry. This gastroparesis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gastroparesis market size has grown steadily in recent years. It will grow from $6.84 billion in 2024 to $7.15 billion in 2025 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to aging population, increasing prevalence of diabetes, improved understanding of gastrointestinal disorders, evolving treatment protocols, growing awareness about gastroparesis.

The gastroparesis market size is expected to see strong growth in the next few years. It will grow to $8.78 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to development of novel therapeutic options, expansion of personalized medicine approaches, integration of digital health solutions, rise in healthcare infrastructure, increasing focus on early diagnosis. Major trends in the forecast period include advancements in gastric electrical stimulation therapy, growing research in stem cell therapy, adoption of minimally invasive surgical interventions, increased use of wearable health monitoring devices, focus on patient-centric care models.

The forecast of 5.3% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade barriers on gastric electrical stimulators and prokinetic drugs from Canada and Germany could elevate treatment costs by 40%, forcing patients to choose less effective options and increasing hospitalizations for refractory cases. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated growth in healthcare expenditure is expected to drive the expansion of the gastroparesis market in the coming years. Healthcare expenditure encompasses the total resources allocated to health services, including costs associated with hospitals, medical professionals, nursing, dental care, medications, and public health initiatives. Factors such as an aging population, advancements in medical technology, an increasing prevalence of chronic diseases, and heightened consumer expectations for enhanced healthcare services contribute to the rise in healthcare spending. This increase benefits the gastroparesis market by providing additional financial support for research and development, broadening treatment options, and improving patient access to specialized healthcare services. For instance, a report from the Office for National Statistics, a UK-based government department, indicated that healthcare spending in the UK rose by 5.6% from 2022 to 2023, compared to a growth rate of 0.9% in 2022. In 2023, the UK's healthcare expenditure reached approximately $317.63 billion (£292 billion). Thus, the growth in healthcare expenditure is propelling the gastroparesis market.

The rapid increase in diabetes prevalence is projected to drive the growth of the gastroparesis market in the future. Diabetes is a chronic medical condition characterized by elevated blood glucose levels due to the body's inability to produce sufficient insulin or utilize the insulin it does produce effectively. The rise in diabetes cases significantly heightens the risk of developing gastroparesis, as diabetes is a key factor contributing to the at-risk population for this condition. For example, data from the Australian Bureau of Statistics, an Australian government agency, revealed that in 2022, 5.3% of the Australian population (approximately 1.3 million individuals) had diabetes, a significant increase from 3.3% in previous years. Consequently, the rapid surge in diabetes prevalence is fueling the growth of the gastroparesis market.

The anticipated growth of the gastroparesis market is expected to be driven by the increasing proportion of aging individuals. Aging individuals refer to those who are advancing in age or undergoing the aging process. The aging population significantly impacts the gastroparesis market due to an elevated prevalence among older individuals, associations with age-related conditions, and distinctive challenges in diagnosing and managing gastroparesis in the elderly. For example, in June 2023, the United States Census Bureau, a US-based government agency, reported a 0.2-year increase in the country's median age to 38.9 years in 2022 from 2021 to 2022, indicating a continued aging trend in the population. Hence, the growing proportion of aging individuals is propelling the gastroparesis market.

Major companies in the gastroparesis market are investing in innovative devices to enhance their market position and profitability. Devices designed for gastroparesis treatment are medical tools or equipment aimed at managing or alleviating symptoms related to delayed stomach emptying. For instance, in 2022, Enterra Medical Inc., a US-based medical device company, introduced the Enterra Therapy for treating gastroparesis. The Enterra Therapy system utilizes an implanted neurostimulator to deliver gentle electrical pulses, offering potential relief for symptoms such as chronic nausea and vomiting associated with gastroparesis. This therapy is intended for individuals aged 18 to 70 experiencing chronic, intractable (drug-refractory) nausea and vomiting linked to gastroparesis of diabetic or idiopathic origin.

Major companies in the gastroparesis market are also developing drugs to bolster their profitability. Drugs used in gastroparesis treatment serve various purposes to address symptoms associated with delayed stomach emptying. For example, in December 2023, Vanda Pharmaceuticals Inc., a US-based biopharmaceutical company, announced that the U.S. FDA had accepted the New Drug Application for Tradipitant. This development represents a significant step toward potential approval for treating gastroparesis, with the FDA setting the decision date for Tradipitant under the Prescription Drug User Fee Act (PDUFA) on September 18, 2024. If successful, Tradipitant would be the first FDA-approved novel drug for gastroparesis in over 40 years, marking a significant milestone in more than three decades for a drug specifically undergoing FDA review for gastroparesis.

Major companies operating in the gastroparesis market include Pfizer Inc., GlaxoSmithKline plc., Abbott Laboratories Inc., AstraZeneca Plc., Medtronic Plc., Takeda Pharmaceutical Company Limited, Johnson And Johnson Services Inc., Teva Pharmaceutical Industries Ltd, AbbVie Inc., Boston Scientific Corporation, Bausch Health Companies Inc., Cadila Pharmaceuticals Ltd., Daewoong Pharmaceutical co. ltd, ReGenXBio Inc., ANI Pharmaceuticals Inc., Dompe Farmaceutici S.p.A, Sucampo Pharmaceuticals Inc., Ironwood Pharmaceuticals Inc., Theravance Biopharma Inc., RedHill Biopharma Ltd., Valeant Pharmaceuticals International Inc., CinRx Pharma LLC., Ritter Pharmaceuticals Inc., Evoke Pharma Inc., Metacrine Inc., Neurogastrx Inc.

North America was the largest region in the gastroparesis market in 2024. The regions covered in the gastroparesis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the gastroparesis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gastroparesis market consists of sales of metoclopramide, domperidone, and erythromycin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gastroparesis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gastroparesis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for gastroparesis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gastroparesis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Gastroparesis Market Characteristics

3. Gastroparesis Market Trends And Strategies

4. Gastroparesis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Gastroparesis Growth Analysis And Strategic Analysis Framework

6. Gastroparesis Market Segmentation

7. Gastroparesis Market Regional And Country Analysis

8. Asia-Pacific Gastroparesis Market

9. China Gastroparesis Market

10. India Gastroparesis Market

11. Japan Gastroparesis Market

12. Australia Gastroparesis Market

13. Indonesia Gastroparesis Market

14. South Korea Gastroparesis Market

15. Western Europe Gastroparesis Market

16. UK Gastroparesis Market

17. Germany Gastroparesis Market

18. France Gastroparesis Market

19. Italy Gastroparesis Market

20. Spain Gastroparesis Market

21. Eastern Europe Gastroparesis Market

22. Russia Gastroparesis Market

23. North America Gastroparesis Market

24. USA Gastroparesis Market

25. Canada Gastroparesis Market

26. South America Gastroparesis Market

27. Brazil Gastroparesis Market

28. Middle East Gastroparesis Market

29. Africa Gastroparesis Market

30. Gastroparesis Market Competitive Landscape And Company Profiles

31. Gastroparesis Market Other Major And Innovative Companies

32. Global Gastroparesis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gastroparesis Market

34. Recent Developments In The Gastroparesis Market

35. Gastroparesis Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기